| Literature DB >> 35371925 |
Josée LeBlanc1, France Talbot1, Vanessa Fournier1, Nickolai Titov2, Blake F Dear2.
Abstract
Young adults are less likely to use traditional mental health services than adults. iCBT may be more youth friendly, but its access remains limited in several countries. This study aims to evaluate the feasibility of a minimally monitored transdiagnostic iCBT program translated from English to French and offered in Canada for the treatment of anxiety and depression among young adults. The impact of the program on resilience was also assessed. Twenty-five participants from community and university samples were included in the analyses in two separate single-group feasibility trials with a 3-month follow-up. Feasibility outcomes were attrition, adherence, treatment acceptability and treatment gains. Outcome measures included the Patient Health Questionnaire 9-item (PHQ-9), Generalized Anxiety Disorder 7-item (GAD-7) and Connor-Davidson Resilience Scale (CD-RISC). In Trial 1 (N = 10), recruiting among the general population proved to be challenging. Low adherence (20%) and high attrition (80%) rates were observed. Methodological changes to recruitment were made and a second trial was conducted among university students using incentives (N = 15). About half of the participants completed treatment (55%, n = 8/15), 12/15 provided post-treatment data and 8/15 provided 3-month follow-up data. All study completers (100%; n = 14) reported they would recommend the program. Mixed effects model analyses revealed significant and large pre-post treatment reductions on the PHQ-9 and GAD-7 (Cohen's d = 1.09 and 1.64 respectively) with treatment gains maintained at follow-up. Moderate improvements were found on the CD-RISC post-treatment with further gains at follow-up (ds = 0.55 and 1.10 respectively). These finding suggest that future research on this French-Canadian version of the Mood Mechanic Course is feasible with appropriate attention to recruitment. Translating existing iCBT interventions and using minimal monitoring may be an optimal first step to initiate the cross-cultural dissemination of iCBT while increasing access to treatments among young adults. Lessons learned are discussed.Entities:
Keywords: Anxiety; Depression; French; Internet-delivered cognitive behavioral therapy (iCBT); Resilience; Young adults
Year: 2022 PMID: 35371925 PMCID: PMC8971854 DOI: 10.1016/j.invent.2022.100529
Source DB: PubMed Journal: Internet Interv ISSN: 2214-7829
Fig. 1Participant flow in Trial 1 (left) and Trial 2 (right).
Sociodemographic and mental health characteristics of the participants in each trial.
| Variable | Trial 1 | Trial 2 | ||
|---|---|---|---|---|
| n | % | n | % | |
| Gender | ||||
| Man | 2 | 20 | 3 | 20 |
| Woman | 8 | 80 | 12 | 80 |
| Age | ||||
| Mean (SD) | 21.6 (1.9) | 19.4 (2.1) | ||
| Range | 18 to 25 | 18 to 25 | ||
| Marital status | ||||
| Married/common law | 1 | 10 | 13 | 86.7 |
| Single | 9 | 90 | 2 | 13.3 |
| Education (completed) | ||||
| High school | 4 | 40 | 11 | 73.4 |
| College | 1 | 10 | 1 | 6.7 |
| University | 5 | 50 | 3 | 20 |
| Occupation | ||||
| Full-time student | 7 | 70 | 14 | 87.5 |
| Part-time student | 1 | 10 | 1 | 6.3 |
| Full-time employment | 2 | 20 | 0 | 0 |
| Previously diagnosed with a mental health disorder | 3 | 30 | 3 | 20 |
| Previously received psychotherapy | 5 | 50 | 8 | 53.3 |
| Currently taking psychotropic medication | 4 | 40 | 2 | 13.3 |
Content of the Mood Mechanic Course.
| Lesson | Lesson content | Duration | Additional resources |
|---|---|---|---|
| Lesson 1 | Psychoeducation on anxiety and depression, CBT model and symptom identification. Information on the prevalence of anxiety disorders and depression and on how they can interfere with life goals. Description of how cognitive, behavioral and physical symptoms can contribute to poor emotional health. | 1 week | Sleep management |
| Lesson 2 | Thought monitoring and challenging. Strategies to generate realistic cognitions. | 2 weeks | Structured problem solving |
| Lesson 3 | Hyperarousal/relaxation and hypo-arousal/pleasant activities scheduling. Strategies for physical de-arousal and for re-engaging in reinforcing activities. | 1 week | Risk calculation |
| Lesson 4 | Avoidance and safety behaviors in relation with anxiety and depression along with graded exposure. | 2 weeks | Assertive communication |
| Lesson 5 | Information about problem-solving, relapse prevention, and emotional well-being maintenance. | 2 weeks |
Means, standard deviations and effect sizes (Cohen's d) for the observed and estimated marginal means for Trial 1.
| Variable | Observed Means (SD) | Estimated Mean (SD) | Effect sizes | ||||||
|---|---|---|---|---|---|---|---|---|---|
| T1 | W1 | W2 | W3 | T1 | W1 | W2 | W3 | T1-W3 | |
| PHQ | 15.00 (4.3) | 11.22 (3.11) | 10.40 (4.10) | 8.67 (5.05) | 15.00 (4.08) | 11.21 (2.88) | 10.39 (3.16) | 8.52 (4.05) | 1.56 |
| GAD | 12.50 (3.17) | 10.22 (4.32) | 10.29 (5.09) | 6.17 (2.86) | 12.5 (3.00) | 10.25 (4.02) | 8.44 (1.87) | 6.16 (2.56) | 1.58 |
Note. T1 = pre-treatment; W1 = week 1; W2 = week 2; W3 = week 3.
Means, standard deviations and effect sizes (Cohen's d) for the observed and estimated marginal means for Trial 2.
| Variable | Observed Means (SD) | Estimated Mean (SD) | Effect sizes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | W3 | T2 | T3 | T1 | W3 | T2 | T3 | Pre-post | Pre-W3 | W3-post | Post-follow-up | Pre-follow-up | |
| PHQ | 11.27 (5.93) | 6.85 (5.38) | 4.55 (3.8) | 4.00 (1.51) | 11.27 (5.73) | 6.92 (4.96) | 4.53 (3.45) | 3.96 (1.55) | 1.09 | 0.97 | 0.52 | 0.15 | 1.16 |
| GAD | 10.8 (3.97) | 7.15 (5.05) | 3.91 (2.70) | 5.13 (3.40) | 10.8 (3.87) | 7.2 (4.69) | 3.96 (2.56) | 5.06 (2.90) | 1.64 | 0.71 | 0.97 | 0.31 | 1.1 |
| RISC | 59.13 (10.30) | – | 64.91 (9.43) | 74.25 (8.46) | 59.13 (2.57) | – | 64.867 (2.07) | 74.22 (1.69) | 0.55 | – | – | 1.10 | 1.59 |
| SPIN | 22.2 (13.58) | – | 13 (9.75) | – | 22.2 (13.13) | – | 12.95 (8.25) | – | 0.62 | – | – | – | – |
| PAS | 22.47 (6.84) | – | 17.73 (5.00) | – | 22.47 (6.62) | – | 17.75 (4.34) | – | 0.63 | – | – | – | – |
| LSQ | 23.07 (4.37) | – | 26.73 (3.58) | – | 23.07 (4.22) | – | 26.77 (3.25) | – | 0.88 | – | – | – | – |
Note. T1 = pre-treatment; W3 = week 3; T2 = post-treatment; T3 = follow-up.
Fig. 2Estimated marginal means over time for the GAD-7 and PHQ-9 in Trial 1 and Trial 2.